Evidence map›Paper›PMID 39062580›Full record

ReviewBiomolecules2024

Calreticulin-Enigmatic Discovery.

Gillian C Okura, Alamelu G Bharadwaj, David M Waisman

Abstract readHistorical ArticleReview
In one paragraph

Review in Biomolecules, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Gillian C OkuraDepartment of Pathology, Dalhousie University, Halifax, NS B3H 1X5, Canada.ORCID 0009-0006-9823-3591
Alamelu G BharadwajDepartment of Pathology, Dalhousie University, Halifax, NS B3H 1X5, Canada.
David M WaismanDepartment of Pathology, Dalhousie University, Halifax, NS B3H 1X5, Canada.ORCID 0000-0002-5097-9662

Funding

Canadian Cancer Society and the J.D. Irving, Limited - Excellence in Cancer Research Fund grant #707176
6 · The paper itself

Abstract

Calreticulin (CRT) is an intrinsically disordered multifunctional protein that plays essential roles intra-and extra-cellularly. The Michalak laboratory has proposed that CRT was initially identified in 1974 by the MacLennan laboratory as the high-affinity Ca

Indexed as

CalreticulinAnimalsHistory, 20th CenturyMuscle, SkeletalProteomicsRabbitsReproducibility of ResultsSarcoplasmic ReticulumCalreticulincalregulincalreticulincalsequestrinendoplasmic reticulumessential thrombocythemiahigh-affinity calcium-binding protein (HACBP)Michalaksarcoplasmic reticulum

Identifiers

PMID39062580
PMCPMC11275038

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.